Sulfonyl-containing phenyl-pyrrolyl pentane analogues: Novel non-secosteroidal vitamin D receptor modulators with favorable physicochemical properties, pharmacokinetic properties and anti-tumor activity

被引:9
作者
Kang, Zi-Sheng [1 ]
Wang, Cong [1 ]
Han, Xiao-Lin [1 ]
Wang, Bin [1 ]
Yuan, Hao-Liang [1 ]
Hou, Si-Yuan [1 ]
Hao, Mei-Xi [1 ]
Du, Jun-Jie [1 ]
Li, Yan-Yi [1 ]
Zhou, An-Wei [1 ]
Zhang, Can [1 ]
机构
[1] China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab Drug Discovery Metab Dis, Ctr New Drug Discovery, 24 Tong Jia Xiang, Nanjing 210009, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Vitamin D receptor (VDR); Non-secosteroidal; Physicochemical properties; Pharmacokinetic properties; Anti-tumor activity; BIOLOGICAL EVALUATION; MOLECULAR-MECHANISMS; PROSTATE-CANCER; PHASE-II; LIGANDS; HYPERCALCEMIA; PANCREATITIS; PROGRESSION; EXPRESSION; SKELETON;
D O I
10.1016/j.ejmech.2018.08.085
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Modulating the vitamin D receptor (VDR) is an effective way to treat for cancer. We previously reported a potent non-secosteroidal VDR modulator (sw-22) with modest anti-tumor activity, which could be due to its undesirable physicochemical and pharmacokinetic properties. In this study, we investigated the structure-activity and structure-property relationships around the 2'-hydroxyl group of sw-22 to improve the physicochemical properties, pharmacokinetic properties and anti-tumor activity. Compounds 19a and 27b, the potent non-secosteroidal VDR modulators, were identified as the most effective molecules in inhibiting the proliferation of three cancer cell lines, particularly breast cancer cells, with a low IC50 via the distribution of cell cycle and induction of apoptosis by stimulating the expression of p21, p27 and Bax. Further investigation revealed that 19a and 27b possessed favorable rat microsomal metabolic stability (2.22 and 2.3 times, respectively, more stable than sw-22), solubility (43.9 and 50.2 times, respectively, more soluble than sw-22) and in vivo pharmacokinetic properties. In addition, 19a and 27b showed excellent in vivo anti-tumor activity without cause hypercalcemia, which is the main side effect of marketed VDR modulators. In summary, the favorable physicochemical properties, pharmacokinetic properties and anti-tumor activity of 19a and 27b highlight their potential therapeutic applications in cancer treatment. (C) 2018 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1174 / 1191
页数:18
相关论文
共 33 条
[1]   Hypercalcaemia and hypocalcaemia: finding the balance [J].
Body, Jean-Jacques ;
Niepel, Daniela ;
Tonini, Giuseppe .
SUPPORTIVE CARE IN CANCER, 2017, 25 (05) :1639-1649
[2]   Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3 [J].
Boehm, MF ;
Fitzgerald, P ;
Zou, AH ;
Elgort, MG ;
Bischoff, ED ;
Mere, L ;
Mais, DE ;
Bissonnette, RP ;
Heyman, RA ;
Nadzan, AM ;
Reichman, M ;
Allegretto, EA .
CHEMISTRY & BIOLOGY, 1999, 6 (05) :265-275
[3]   STRUCTURE-FUNCTION-RELATIONSHIPS IN THE VITAMIN-D ENDOCRINE SYSTEM [J].
BOUILLON, R ;
OKAMURA, WH ;
NORMAN, AW .
ENDOCRINE REVIEWS, 1995, 16 (02) :200-257
[4]  
Bouillon R., 2004, VIT D P 12 WORKSH VI
[5]   Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice [J].
Bouillon, Roger ;
Carmeliet, Geert ;
Verlinden, Lieve ;
van Etten, Evelyne ;
Verstuyf, Annemieke ;
Luderer, Hilary F. ;
Lieben, Liesbet ;
Mathieu, Chantal ;
Demay, Marie .
ENDOCRINE REVIEWS, 2008, 29 (06) :726-776
[6]   Vitamin D analogs: Therapeutic applications and mechanisms for selectivity [J].
Brown, Alex J. ;
Slatopolsky, Eduardo .
MOLECULAR ASPECTS OF MEDICINE, 2008, 29 (06) :433-452
[7]   A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma [J].
Dalhoff, K ;
Dancey, J ;
Astrup, L ;
Skovsgaard, T ;
Hamberg, KJ ;
Lofts, FJ ;
Rosmorduc, O ;
Erlinger, S ;
Hansen, JB ;
Steward, WP ;
Skov, T ;
Burcharth, F ;
Evans, TRJ .
BRITISH JOURNAL OF CANCER, 2003, 89 (02) :252-257
[8]   Vitamin D signalling pathways in cancer: potential for anticancer therapeutics [J].
Deeb, Kristin K. ;
Trump, Donald L. ;
Johnson, Candace S. .
NATURE REVIEWS CANCER, 2007, 7 (09) :684-700
[9]   The role of vitamin D in reducing cancer risk and progression [J].
Feldman, David ;
Krishnan, Aruna V. ;
Swami, Srilatha ;
Giovannucci, Edward ;
Feldman, Brian J. .
NATURE REVIEWS CANCER, 2014, 14 (05) :342-357
[10]   Vitamin D and cancer: a review of molecular mechanisms [J].
Fleet, James C. ;
DeSmet, Marsha ;
Johnson, Robert ;
Li, Yan .
BIOCHEMICAL JOURNAL, 2012, 441 :61-76